Profile change history

What changed for Tirzepatide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Tirzepatide identity.

225Total events
219Record additions
6Version changes
5Cited source years

Source-published notices

Research integrity notices

Method and complete cohort →

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT07463846

ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

Cited source date

Before
2026-08-12
After
2026-11-12

Source observed date

Before
2026-08-13
After
2026-11-15

Cited source records

Before
ctg-observation-nct07463846-2026-08-12-3a462c76c655
After
ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

Headline citations

Before
ctg-observation-nct07463846-2026-08-12-3a462c76c655
After
ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

Summary citations

Before
ctg-observation-nct07463846-2026-08-12-3a462c76c655
After
ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]

Source snapshot commitment

Before
6ae7bcba9aa2922ec5cb26cb9ce412469fb389b44aa70fa29776d480876bf7e7
After
419d66b2ad3451743220da2eef392971ff3a949579c07dc08771fc73c36e6ac5
Record updated

ClinicalTrials.gov record NCT07734792

ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

Cited source date

Before
2026-07-29
After
2026-11-12

Source observed date

Before
2026-08-10
After
2026-11-15

Cited source records

Before
ctg-observation-nct07734792-2026-07-29-16e12449ec7c
After
ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

Headline citations

Before
ctg-observation-nct07734792-2026-07-29-16e12449ec7c
After
ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

Summary citations

Before
ctg-observation-nct07734792-2026-07-29-16e12449ec7c
After
ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]

Source snapshot commitment

Before
e48a94be6cabaa41355f8224bd8766914e7dba01f18d17df87aba2ad5484b22a
After
4bc75d2c3256725d011167df3f4a7d859b4c36321408b50414bc7c7cf8b0623d
Profile status changed

Tirzepatide profile

We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026).

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
U.S. label record
After
FDA-approved as Mounjaro and Zepbound

Profile summary

Before
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
After
A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.

Evidence note

Before
The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.

Cited source records

Before
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity
After
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-glp1-label-warning-request-2026, fda-glp1-bulks-proposal-2026, fda-unapproved-glp1-concerns-2026-r2

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]
After
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]; U.S. Food and Drug Administration [sources: fda-mounjaro-s044-s045-approval-2026, fda-unapproved-glp1-concerns-2026-r2]

Claim citations

Before
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40
After
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-drugs-nda215866-2022-05-13-20c7192d69ff, fda-drugs-nda217806-2023-11-08-1fa405392d95, fda-mounjaro-s044-s045-approval-2026; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-mounjaro-s044-s045-approval-2026, fda-zepbound-s041-approval-2026, fda-unapproved-glp1-concerns-2026-r2
Correction

Tirzepatide profile

We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Cited source records

Before
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023, fda-tirzepatide-identity
After
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023, fda-tirzepatide-identity

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38]
After
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]

Claim citations

Before
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
After
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40
Profile updated

Tirzepatide profile

We added search aliases that the cited FDA substance-identity record maps to this active ingredient. The profile's status did not change.

PeptideScanner change date
July 29, 2026
Evidence lane
Profile

Related names

Before
Zepbound
After
Zepbound, Mounjaro

Cited source records

Before
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023
After
dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023, fda-tirzepatide-identity

Claim citations

Before
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
After
name: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; aliases: fda-tirzepatide-identity; category: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; status: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38; summary: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38, fda-tirzepatide-2023; evidenceNote: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38
Profile updated

Tirzepatide profile

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A GIP and GLP-1 receptor agonist represented by an exact current Zepbound label record and an FDA notice.
After
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.

Collection chronology

Evidence added to PeptideScanner

Browse all 219 connected records →

Showing the latest 100 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 16, 2026.

Record added

Tirzepatide in Adolescents With Obesity: Research Summary.

PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 15, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT05433584

PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05536804

PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05556512

PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06162715

PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06191848

PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06603571

PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06700538

PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06774079

PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06854614

PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06857942

PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06861439

PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06911203

PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06937086

PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06937099

PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07078838

PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07099742

PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07481747

PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07504172

PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07527910

PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 29, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07697391

PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07782359

PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 27, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07803744

PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07811895

PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07812636

PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07817875

PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07825857

PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07829198

PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 18, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07842640

PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
September 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07846865

PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07847515

PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07866183

PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07868354

PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 16, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07874828

PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07881432

PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 3, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07881458

PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07889453

PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 22, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07889648

PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 22, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07893457

PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
October 26, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07906041

PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07929571

PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07931235

PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
November 14, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Record added

Anaphylaxis to tirzepatide confirmed by positive skin prick testing.

PubMed lists PMID 42735799 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Journal Article, with publication-date metadata of 2026-09-14 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata
Record added

Tirzepatide among patients with psoriasis and obesity.

PubMed lists PMID 42810204 in Medicina clinica as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
September 29, 2026
Evidence lane
Literature metadata
Record added

Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.

PubMed lists PMID 42831032 in Obesity pillars as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 6, 2026
Evidence lane
Literature metadata
Record added

Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice.

PubMed lists PMID 42922752 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 30, 2026
Evidence lane
Literature metadata
Record added

PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide.

PubMed lists PMID 42969740 in Molecular pharmaceutics as Journal Article, with publication-date metadata of 2026-11-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 2, 2026
Evidence lane
Literature metadata
Record added

Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity.

PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Literature metadata
Record added

Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study.

PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 14, 2026
Evidence lane
Literature metadata
Record added

A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series.

PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 14, 2026
Evidence lane
Literature metadata
Record added

Tirzepatide DailyMed SPL version 40

DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
September 15, 2026
Cited source date
September 2, 2026
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT06439277

PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
September 9, 2026
Cited source date
September 4, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07247084

PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
September 9, 2026
Cited source date
September 9, 2026
Evidence lane
Clinical trials
Record added

Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice.

PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
September 9, 2026
Cited source date
September 4, 2026
Evidence lane
Literature metadata
Record added

Tirzepatide DailyMed SPL version 12

DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 4, 2024
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 14

DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
December 30, 2024
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 15

DailyMed lists Structured Product Labeling version 15 for the reviewed Tirzepatide label family with a published date of 2025-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
January 6, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 16

DailyMed lists Structured Product Labeling version 16 for the reviewed Tirzepatide label family with a published date of 2025-02-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 7, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 17

DailyMed lists Structured Product Labeling version 17 for the reviewed Tirzepatide label family with a published date of 2025-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 27, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 18

DailyMed lists Structured Product Labeling version 18 for the reviewed Tirzepatide label family with a published date of 2025-03-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 21, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 19

DailyMed lists Structured Product Labeling version 19 for the reviewed Tirzepatide label family with a published date of 2025-04-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
April 14, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 2

DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 14, 2023
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 21

DailyMed lists Structured Product Labeling version 21 for the reviewed Tirzepatide label family with a published date of 2025-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
May 5, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 22

DailyMed lists Structured Product Labeling version 22 for the reviewed Tirzepatide label family with a published date of 2025-05-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
May 29, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 23

DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
July 25, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 28

DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 17, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 3

DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
November 16, 2023
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 30

DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
December 31, 2025
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 31

DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
January 23, 2026
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 32

DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 5, 2026
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 36

DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
February 26, 2026
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 37

DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
March 3, 2026
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 38

DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
May 6, 2026
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 5

DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
April 12, 2024
Evidence lane
Regulatory
Record added

Tirzepatide DailyMed SPL version 8

DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
August 8, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 2022-18523

The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
August 29, 2022
Evidence lane
Regulatory
Record added

Federal Register notice 2023-18026

The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
August 22, 2023
Evidence lane
Regulatory
Record added

Federal Register notice 2024-04157

The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
February 29, 2024
Evidence lane
Regulatory
Record added

Federal Register notice 2025-20548

The Federal Register published notice 2025-20548, attributed to FDA and its parent HHS department, on 2025-11-21. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
November 21, 2025
Evidence lane
Regulatory
Record added

Federal Register notice 2025-22131

The Federal Register published notice 2025-22131, attributed to FDA and its parent HHS department, on 2025-12-05. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

PeptideScanner change date
August 21, 2026
Cited source date
December 5, 2025
Evidence lane
Regulatory
Record added

Federal Register notice 2026-08552

The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
May 1, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-12937

The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.

PeptideScanner change date
August 21, 2026
Cited source date
June 26, 2026
Evidence lane
Regulatory
Record added

Federal Register notice 2026-15285

The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

PeptideScanner change date
August 21, 2026
Cited source date
July 29, 2026
Evidence lane
Regulatory
Record added

Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD.

PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 16, 2026
Cited source date
April 27, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT06965413

PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 14, 2026
Cited source date
August 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07463846

PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 14, 2026
Cited source date
August 12, 2026
Evidence lane
Clinical trials
Record added

Real world tirzepatide treatment for fatty liver disease.

PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
April 27, 2026
Evidence lane
Literature metadata
Record added

Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome.

PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata
Record added

Facial nodules following filler injections after initiating compounded tirzepatide use.

PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata
Record added

Inflammation-mediated facial nodules to compounded tirzepatide.

PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 14, 2026
Cited source date
August 14, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT06651177

PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
August 11, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06727331

PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06893211

PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06934642

PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 15, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06935838

PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 8, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07046819

PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
August 12, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07191873

PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07257484

PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

PeptideScanner change date
August 13, 2026
Cited source date
July 22, 2026
Evidence lane
Clinical trials